FUAN PHARMACEUTICAL (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.62 CNY | +1.12% |
|
-1.90% | -17.35% |
| Apr. 08 | Fuan Pharm Unit's Hemorrhage Drug Gets Registration Certificate from China's Drug Regulator | MT |
| Feb. 22 | Drugs of Fuan Pharma's Unit Passes Regulatory Evaluation | MT |
| Sales 2021 | 2.45B 339M | Sales 2022 | 2.42B 334M | Capitalization | 4.28B 591M |
|---|---|---|---|---|---|
| Net income 2021 | -297M -40.99M | Net income 2022 | 205M 28.29M | EV / Sales 2021 | 2.44 x |
| Net cash position 2021 | 95.96M 13.24M | Net Debt 2022 | 10.45M 1.44M | EV / Sales 2022 | 1.77 x |
| P/E ratio 2021 |
-20.5
x | P/E ratio 2022 |
21.2
x | Employees | 3,229 |
| Yield 2021 * |
-
| Yield 2022 |
1.39% | Free-Float | 17.16% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.12% | ||
| 1 week | -1.90% | ||
| Current month | -5.24% | ||
| 1 month | -2.95% | ||
| 3 months | -2.16% | ||
| 6 months | -13.40% | ||
| Current year | -17.35% |
1 week
3.47
3.67
1 month
3.414.19
Current year
2.924.47
1 year
2.925.15
3 years
2.925.50
5 years
2.929.39
10 years
2.8713.66
| Managers | Title | Age | Since |
|---|---|---|---|
Lu Wang
CEO | Chief Executive Officer | 40 | 21-12-09 |
Xue Song Yu
DFI | Director of Finance/CFO | 55 | 09-09-18 |
Tian Xiang Wang
CHM | Chairman | 68 | 09-09-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tian Xiang Wang
CHM | Chairman | 68 | 09-09-18 |
Lu Wang
CEO | Chief Executive Officer | 40 | 21-12-09 |
Qin Tang
BRD | Director/Board Member | 55 | 09-09-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 3.62 | +1.12% | 12,227,600 |
| 24-04-19 | 3.58 | -0.28% | 11,707,500 |
| 24-04-18 | 3.59 | -1.37% | 16,069,100 |
| 24-04-17 | 3.64 | +6.12% | 24,081,160 |
| 24-04-16 | 3.43 | -7.05% | 31,475,400 |
End-of-day quote Shenzhen S.E., April 21, 2024
More quotes
Fuan Pharmaceutical (Group) Co.,Ltd. is a China-based company principally engaged in the sales of Active Pharmaceutical Ingredients (APIs) and intermediates, preparations and pharmaceuticals. The Company's pharmaceutical products mainly include antibiotics, anti-tumor medicines, respiratory system medicines and specialty medicines. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -17.35% | 595M | |
| +17.88% | 44.31B | |
| +19.87% | 22.17B | |
| +15.23% | 14.62B | |
| +8.06% | 13.12B | |
| +39.21% | 11.58B | |
| -8.96% | 6.96B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.50% | 5.03B |
- Stock Market
- Equities
- 300194 Stock
